Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Zymeworks Inc (ZYME)

Zymeworks Inc (ZYME)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 985,422
  • Shares Outstanding, K 71,047
  • Annual Sales, $ 76,010 K
  • Annual Income, $ -118,670 K
  • EBIT $ -137 M
  • EBITDA $ -127 M
  • 60-Month Beta 1.20
  • Price/Sales 12.81
  • Price/Cash Flow N/A
  • Price/Book 2.38

Options Overview Details

View History
  • Implied Volatility 67.12% ( -3.30%)
  • Historical Volatility 28.52%
  • IV Percentile 37%
  • IV Rank 25.91%
  • IV High 182.17% on 05/06/24
  • IV Low 26.89% on 09/11/24
  • Put/Call Vol Ratio 0.06
  • Today's Volume 35
  • Volume Avg (30-Day) 45
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 848
  • Open Int (30-Day) 4,556

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.40
  • Number of Estimates 5
  • High Estimate -0.14
  • Low Estimate -0.75
  • Prior Year -0.41
  • Growth Rate Est. (year over year) +2.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.99 +14.26%
on 10/03/24
14.05 -2.49%
on 10/16/24
+1.15 (+9.16%)
since 09/30/24
3-Month
9.40 +45.67%
on 08/05/24
14.05 -2.49%
on 10/16/24
+3.28 (+31.48%)
since 07/30/24
52-Week
6.79 +101.77%
on 10/31/23
14.05 -2.49%
on 10/16/24
+6.71 (+95.99%)
since 10/30/23

Most Recent Stories

More News
Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results

ZYME : 13.70 (-1.23%)
Zymeworks Announces Participation in Upcoming Investor Conferences

ZYME : 13.70 (-1.23%)
Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

ZYME : 13.70 (-1.23%)
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers

ZYME : 13.70 (-1.23%)
Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024

ZYME : 13.70 (-1.23%)
Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players

/CNW/ -- USA News Group – In the oncology world, there's been plenty to celebrate recently, with cancer deaths falling by 33% in the last 30 years. However,...

ONCY : 1.1500 (-3.36%)
NVS : 108.40 (-1.37%)
LNTH : 109.84 (+0.42%)
STRO : 3.25 (-8.71%)
ZYME : 13.70 (-1.23%)
ONC.TO : 1.59 (-3.64%)
Recent Breakthroughs in Cancer Research Could Impact These Key Companies

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group – In the oncology world, there’s...

ONCY : 1.1500 (-3.36%)
ONC.TO : 1.59 (-3.64%)
NVS : 108.40 (-1.37%)
LNTH : 109.84 (+0.42%)
STRO : 3.25 (-8.71%)
ZYME : 13.70 (-1.23%)
InMed Pharmaceuticals (NASDAQ: INM) Names New Chief Financial Officer

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, has announced the appointment of Netta Jagpal,...

INM : 0.2659 (-9.22%)
QBTS : 1.0600 (-6.19%)
ZYME : 13.70 (-1.23%)
Zymeworks to Join NASDAQ Biotech Index

Zymeworks Inc. (NASDAQ: ZYME) gained ground Friday, as the clinical-stage biotechnology company developing ...

ZYME : 13.70 (-1.23%)
Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – September 22, 2023 – USA News Group  –  Despite the potential federal funding challenges due to the recent debt ceiling...

RY : 120.89 (-2.18%)
RY.TO : 168.39 (-2.01%)
ONCY : 1.1500 (-3.36%)
ONC.TO : 1.59 (-3.64%)
JAZZ : 110.03 (-2.78%)
ZYME : 13.70 (-1.23%)
AMGN : 320.16 (+1.46%)
PTGX : 45.84 (-3.74%)

Business Summary

Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered...

See More

Key Turning Points

3rd Resistance Point 14.40
2nd Resistance Point 14.19
1st Resistance Point 13.94
Last Price 13.70
1st Support Level 13.48
2nd Support Level 13.27
3rd Support Level 13.02

See More

52-Week High 14.05
Last Price 13.70
Fibonacci 61.8% 11.28
Fibonacci 50% 10.42
Fibonacci 38.2% 9.56
52-Week Low 6.79

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar